Artaud F, Lee PC, Mangone G, et al. - Researchers conducted the study for analyzing the longitudinal relation of dopamine agonists (DA) use with body mass index (BMI) change and weight gain in Parkinson disease (PD). In a cohort of 356 patients with PD annually followed up to 6 years, BMI, antiparkinsonian drugs use, and impulse control disorders have been evaluated at each visit. Using latent class mixed models, DA dose trajectories were estimated. In DA users above 6 years, weight increased and DA usage was correlated with an increased incidence of weight gain. Compulsive eating has partly clarified these correlations. Alternatively, in levodopa users, weight decreased. In PD patients, such results require close monitoring of compulsive eating and weight.